SPEAKER PRESENTATIONS
Speaker presentations have been attached where consent has been given by speakers to allow delegates access to their presentation slides.
WEDNESDAY 20 OCTOBER
OPENING & PLENARY
9.00AM – 11.00AM
PLENARY 1 -
Mr James C. Greenwood, President and CEO, Biotechnology Industry Organization, Washington D.C., United States - NO PRESENTATION USED
PLENARY 2 -
Dr David Nicholson, Senior Vice President, Worldwide Licensing and Knowledge Management, Merck Research Laboratories, New Jersey, United States
Dr Bornadata Bain, Global Research and Analysis Director, Datamonitor Healthcare, United States
CONFERENCE SESSIONS
11.30AM – 1.00PM
Cell therapy commercialisation: Look think and act from a different point of view
- Chair: Dr David Haylock, Research Scientist, Materials Science and Engineering, CSIRO
- Associate Professor Geoff Symonds, Chief Scientific Officer, Calimmune Australia – PRESENTATION NOT MADE AVAILABLE
- Dr Kilian Kelly, Director Regulatory and Clinical, Mesoblast Limited
- Dr Sunil Mehta, Director Technology Development, KBI Biopharma Inc., North Carolina, United States
- Ian Fitzpatrick, Manager Manufacturing Innovation Group, Invetech Pty Ltd
Regulation in Key Markets
- Chair: Alek Safarian, Chief Executive Officer, Novotech
- Michele Yelmene, Regulatory Affairs & Quality Assurance, Advisor to Industry, California, United States
- Dr Chaline Brown, Senior Director Clinical Affairs, Ground Zero Pharmaceuticals Ltd, California, United States
- Dr Dianne Jackson-Matthews, Director, ERA Consulting (Australia) Pty Ltd
Biofuels - Algae as a Factory
- Chair: Dr Susan Pond AM, Professor, Dow Sustainability Program, US Studies Centre
- Associate Professor Ben Hankamer, Director of the Solar Biofuels Consortium, Division of Chemistry and Structural Biology, The Institute for Molecular Bioscience – PRESENTATION NOT MADE AVAILABLE
- Professor Rocky De Nys, Head of Aquaculture, James Cook University - PRESENTATION NOT MADE AVAILABLE
- Dr Sasi Nayar, South Australian Research and Development Institute
International Financing – new options and opportunities
- Chair: Jeremy Curnock – Cook, Managing Director, IB Fund Pty Ltd
- Malcolm Thompson, La Jolla Cove Investors, United States
- Todd C. Davis, Co-Founder and Managing Director, Cowen Healthcare Royalty Partners, United States
- Doug Onsi, Managing Director, Healthcare Ventures, United States
- Rudolf Gygax, Managing Partner, Nextech Venutres Ltd, Switzerland
NO PRESENTATIONS USED IN ABOVE PANEL SESSION
CONFERENCE SESSIONS
2.00PM – 3.30PM
New Technologies for Point of Care
- Chair: Dr David Lester, Director, Health Strategy and Coordination Group, CSIRO
- Andrew Lysikatos, Chief Executive Officer, Axxin
- Dr Andrew Campitelli, Diagnostics Manager, MiniFAB (Aust) Pty Ltd – PRESENTATION NOT MADE AVAILABLE
- Tom Stamp, Director, Blue Curve Pty Ltd
Maximising Australia’s Investment in Medical Research – new approaches to discovery and commercialisation
- Chair: Alex Gosman, Principal, Alex Gosman Consulting
- Rebecca James, Chief Executive, Research Australia
- Dr Nicholas Gruen, Chief Executive Officer, Lateral Economics – NO PRESENTATION USED
- Peter Roberts, Senior Writer, The Australian Financial Review – NO PRESENTATION USED
- Dr Ashley Bates, Head of R&D Alliances Australia & New Zealand, GlaxoSmithKline
Solutions that protect and improve performance
- Chair: Dr Wayne Best, Managing Director, Epichem Pty Ltd
- Karen King, President, DSM Biologics, United States - PRESENATION NOT MADE AVAILABLE
- Dr Christopher Stewart, Director of Business Affairs, MPI Research, United States
- Craig Rogers, Chief Commercial Officer, Nucleus Network
Venture Capital and Life Sciences in Australia Today. How does this compare with the Global Situation?
- Chair and speaker: Dr Michael Hirshorn, Director, Four Hats Capital
- Dr Andrew Baker, Partner, GBS Venture Partners
- Dr David Fisher, Managing Director, Brandon Capital Partners
- Dr Carrie Hillyard, Partner, CM Capital
- Fiona Pak Poy, General Partner, Innovation Capital – PRESENTATION NOT MADE AVAILABLE
- Karl Handelsman, Managing Director, CMEA Capital, San Francisco, United States – NO PRESENTATION USED
CONFERENCE SESSIONS
4:00PM – 5:30PM
Busting the myths about gene patenting
- Chair: Geraldine Farrell, Special Counsel, Griffith Hack Lawyers
- Dr Tania Obranovich, Partner, Davies Collison Cave - PRESENTATION NOT AVAILABLE, please contact speaker directly at TObranovich@davies.com.au with any questions
- Dr Julian Clark, Head of Business Development, Walter and Eliza Hall Institute
Takeover Strategies Workshop
- Peter Howard, Partner Middletons
- Andrew Gaffney, Partner, Middletons
PRESENTATION NOT AVAILABLE FOR WORKSHOP
Translating Hope into Help
- Chair: Ian Thompson, General Manager, Amgen Australia Pty Ltd
- Professor Sean Grimmond, Director, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland – PRESENTATION NOT MADE AVAILABLE
- Associate Professor David Thomas, Medical Oncologist / Head, Sarcoma, Peter MacCallum Cancer Centre – PRESENTATION NOT MADE AVAILABLE
- Dr Pamela Pollock, Vice Chancellor Senior Research Fellow, Cancer Program,
Institute of Health and Biomedical Innovation, Queensland University of Technology – PRESENTATION NOT MADE AVAILABLE
Future-proofing Australia: Products for a sustainable bioeconomy
- Chair: Dr Dianne Glenn, Principal, Corelli Consulting
- Dr Ann Roberts, Project Manager, Plantic Technologies Ltd
- Dr Jens Kroemer, Australian Institute for Bioengineering & Nanotechnology (AIBN) The University of Queensland
- Dr William Lyons, Vice President and General Manager, Boeing Research & Technology Australia
Innovative Business Development Models
- Chair and speaker: Dr Charlie Day, Chief Executive Officer, Melbourne Ventures
Speakers: - Dr James Dromey, Business Development Manager, Walter and Eliza Hall Institute
- Dr Dean Moss, General Manager Life Sciences, UniQuest
- Josh Hexter, Executive Director In-Licensing, BioLineRx Ltd, Israel – PRESENTATION NOT MADE AVAILABLE
THURSDAY 21 OCTOBER
PLENARY 9.00AM - 10.00AM
Millis Oration
- Professor Nadia Rosenthal, Director, Australian Regenerative Medicine Institute, Monash University – PRESENTATION NOT AVAILABLE
CONFERENCE SESSIONS
10.30AM – 12.00PM
Strategies for successful biomarker and companion diagnostics development
- Chair: Dr Matthias Schuster, Scientific Director Dx Assays, Singapore
- Dr Hiram Chipperfield, Consultant, ERA Consulting
- Dr Mervyn Thomas, Director, Althomics Pty Ltd – PRESENTATION NOT MADE AVAILABLE
- Nick Gatsios, Managing Director & Executive Director (Australia), HealthLinx
Big Pharma Scouts – what they want and what you get
- Chair: Glenn Cross, Chief Operating Officer, AusBiotech Ltd
- Dr Phil Kearney, Director, Licensing & External Research, Merck & Co., Inc.
- Dr Ashley Bates, Head of R&D Alliances Australia & New Zealand, GlaxoSmithKline
- Dr Daniel Grant, Director, Asia R&D Business Development, Pfizer Australia
- Dr Stella Xu, Executive Director, Roche Partnering Asia, Shanghai, China
NO PRESENTATIONS USED IN ABOVE PANEL SESSION
Investors Unplugged: Everything you’ve wanted to ask a fund manager, but were afraid to ask
- Chair: Hershel Berry, Managing Partner, Blueprint Life Sciences, United States
Panellists: - Karl Handelsman, Managing Director, CMEA Capital, United States
- Oleg Nodelman, Portfolio Manager/Partner, Biotechnology Value Fund, United States
- Dr Axel Polack, General Partner, TVM Capital GmbH, Germany
- Rajeev Shah, Partner, RA Capital Management LLC, United States
- Dr Rudolf Gygax, Managing Partner, Nextech Venture Ltd, Switzerland
- Lawrence Gozlan, Chief Executive Officer, Scientia Capital, United States
NO PRESENTATIONS USED IN ABOVE PANEL SESSION
Future global trends in the life sciences industry – industry & legal trends
- Chair: Tony Conaghan, Lead Partner, Intellectual Property & Technology Practice, DLA Phillips Fox – Australia
Speakers: - Dr Lisa Haile, Partner Life Sciences Practice, DLA Piper - United States
- Bruce Jenett, Partner Life Sciences Practice, DLA Piper - United States
- Alex Gosman, Principal, Alex Gosman Consulting – NO PRESENTATION USED
- Dr Gabby Fennessy, Manager, Policy and Strategy, Research Australia
CONFERENCE SESSIONS
2.00PM – 3.30PM
Developing Award Winning Medical Devices
- Chair: Dr Greg Roger, Chief Executive Officer, Advanced Surgical Design & Manufacture
Speakers: - Anthony Honeyfield, Design Director, Design + Industry – FOR DETAILED SPEAKER NOTES – CONTACT SPEAKER DIRECTLY info@design-industry.com.au
- Adam Panarello, Engineering Projects Manager (Hardware), Telemedcare Pty Ltd
- Lusia Guthrie, Chief Executive Officer & Managing Director, LBT Innovations Ltd
- David Mulcahy, Vice President Product Development, ResMed Ltd
Understanding the implications of the rapidly evolving US healthcare and regulatory environment
- Chair: Peter Molloy, President, Aquarius Consulting, Nevada, United States
- Jayson Slotnik, Counsel, Foley Hoag LLP, Washington DC, United States
- Hathaway Russell, Patent Attorney, Foley Hoag LLP, Boston, United States - PRESENTATION NOT MADE AVAILABLE
- Dr Paul Ashton, President & CEO, pSivida Corp, United States
Evidence based complementary medicines for human and animal use: International Trends and Opportunities in Integrative Health
- Chair: Lawrence Bremner, Managing Director, The Big Well
- Mr Graeme McRae, Chief Executive Officer, Bioniche Life Sciences, Canada
- Megan Thomas, Jamieson Laboratories Limited, Ontario, Canada – PRESENTATION NOT MADE AVAILABLE
- Dr Lee Ann Murphy, Executive Director, Manitoba Agri-Health Research Network (MAHRN), Manitoba, Canada
- Dr Chris Wahl, Director Business Development, Micropharma, Canada – PRESENTATION NOT MADE AVAILABLE
How does the Australian public market react to news?
- Chair: Ben Gust, Investment Manager, GBS Venture Partners – PRESENTATION NOT MADE AVAILABLE
- Lawrence Gozlan, Chief Executive Officer, Scientia Capital, United States – NO PRESENTATION USED
- David Blake, BioShares – NO PRESENTATION USED
- Michael Lusis, Business Director, Wilson HTM Corporate Finance - PRESENTATION NOT MADE AVAILABLE
- Dr Greg Collier, Chief Executive Officer and Managing Director, ChemGenex Pharmaceuticals – NO PRESENTATION USED
CONFERENCE SESSIONS
4.00PM – 5.30PM
Credible and incredible! How to communicate with investors, regulators and prescribers
- Chair: Dr Christine Wichems, Medical Communications Manager, CSL Limited
- Andy Jane, Partner, CM Capital
- Judy Develin, Coordinator, Market Authorisation Group, Therapeutic Goods Administration
- Associate Professor Karen Woolley, CEO, ProScribe Medical Communications
Research Ethics & Governance – State initiatives for global trials
- Chair: Bill Karanatsios, Client Relationship Manager, Public Healthcare and Medical Research, Victorian Managed Insurance Authority
- Dr Suzanne Hasthorpe, Manager, Department of Health, Victoria
- Sue Jenkins-Marsh, Principal Project Officer, Queensland Health
- Dr Jo Mitchell, Associate Director Research, Ethics and Public Health Training, NSW Health
- Mitch Kirkman, Manager- Process, Training and Quality, Novartis Pharmaceuticals, Australia Pty Limited
Plant biotechnology in Support of the Millennium Development Goals
- Chair: Dr Murray McLaughlin, President & CEO, Sustainable Chemistry Alliance, Ontario, Canada
- Professor German Spangenberg, Executive Director, Biosciences Research Division, Department of Primary Industries & Professor, Plant Genetics and Genomics
La Trobe University - PRESENTATION NOT MADE AVAILABLE - Dr TJ Higgins, Honorary Fellow, CSIRO
- Professor Emeritus Ingo Potrykus, Chairman Humanitarian Golden Rice Board & Network, Switzerland
Deal or No Deal?: Option Based Partnering Deals
- Chair: Robin Coleman, Principal, PharmBio Deals
- Dr Leigh Farrell, VP Business Development, Biota Holdings Ltd
- Dr Richard Treagus, Chief Executive Officer, Acrux Ltd
- Dr Joshua Funder, Partner, GBS Venture Partners
- Dr Shane Storey, Analyst – Healthcare and Biotechnology, Wilson HTM Investment Group
- Dr Fintan Walton, Founder and Chief Executive Officer, PharmaVentures, United Kingdom
PRESENTATIONS MERGED INTO ONE FOR THIS SESSION – LINKED TO SESSION CHAIR, ROBIN COLEMAN
FRIDAY 22 OCTOBER
PLENARY 5 –
- Dr John W. Holaday, Managing Director and CEO, QRxPharma Limited - PRESENTATION NOT AVAILABLE
CONFERENCE SESSIONS
9.30AM – 11.00AM
Building reputation to drive corporate strategy: A masterclass in biotech communications
- Chair and speaker: Sue Charles, Managing Partner, College Hill Life Sciences, London, United Kingdom
- Margaret Stuart, Director, Margaret Stuart and Associates
- Peter Sandbach, Head of Communications, Roche Partnering, F. Hoffmann-La Roche AG, Switzerland
- Nick Woolf, Non Executive Director, Phylogica Limited
PRESENTATIONS MERGED INTO ONE FOR THIS SESSION – LINKED TO SESSION CHAIR, SUE CHARLES
Functional Foods
- Chair: Peter Hobman, General Manager, MG Nutritionals Ltd
- Joe Lederman, Managing Principal, FoodLegal
- Amanda Jones, Principal, Watermark Patent & Trademark
- Dr Andrew Kelly, Executive Director, BioPacificVentures, New Zealand
Think Locally, Act Globally: Successfully taking Australian intellectual capital to the world stage
- Chair: Karen Sinclair, Principal, Watermark Patent & Trade Marks Attorneys, and President, Licensing Executives Society of Australia and New Zealand, Inc.
- Dr Simon Tucker, Vice President Research, Biota Holdings Limited - PRESENTATION NOT MADE AVAILABLE
- Brad O’Connor, Chief Executive Officer, CogState Limited
- Mel Bridges, Chairman and Company Director
CONFERENCE SESSIONS
11.30AM – 1.00PM
Integration of Wireless Medical Devices
- Chair: Dr Scott Martin, Leader, Biomedical Manufacturing Research Theme, CSIRO
Speakers: - Warren Bingham, President – Australia / New Zealand, Given Imaging Pty Ltd
- Peter Lewis, General Manager Business Development, Hydrix
- Dr Jason Chaffey, Chief Technology Officer, bluechiip Pty Ltd - PRESENTATION NOT MADE AVAILABLE
India – beyond contract manufacturing
- Chair and speaker: Mr Swapan Bhattacharya, Managing Director, TCG Lifesciences, West Bengal, India
- Dr Julia Hill, Director, Mantrax Ventures
- Dr Alistair Draffan, Director Drug Discovery, Biota Holdings Ltd - PRESENTATION NOT MADE AVAILABLE
- Dr Arun Bhatt, President, Clininvent Pvt Ltd, India
- Dr Lewis Schulz, Chief Operating Officer, Hatchtech Pty Ltd
Creating Global Value in Product Development: from Proof of Principle to Regulatory Strategy
- Chair: Dr Gabriel Kremmidiotis, Vice President Discovery Research, Bionomics Limited
- Dr Valentia Lee-Brotherton, Director, Toxicology, Ashuren Health Sciences, Canada
- Dr Ken Draper, Senior Director, Scientific Operations, LAB Research Inc., Canada
- Nicholas Peace, Investment Director, Starfish Ventures Pty Ltd – PRESENTATION NOT MADE AVAILABLE
- Dr Pete Smith, Chief Executive Officer, Alchemia Limited
- Dr Michael Thurn, Chief Executive Officer, Mimetica Pty Ltd – PRESENTATION NOT MADE AVAILABLE
